SITC 2024: With a TIL therapy having made it to the market for the first time this year, the CEO of KSQ Therapeutics describes what the next generation of TILs might look like
- Nov 8, 2024
- 1 min read
Qasim Rizvi says he believes TILs can have broad applicability in the solid tumor space. He describes how KSQ is knocking out SOCS1 and REGNASE-1 to solve the problem of T-cell exhaustion. The company's first two programs are now in the clinic.
.png){kind=logo}